Golotimod (SCV-07) is primarily investigated for its immunomodulatory properties, making it a potential candidate in the treatment of various diseases. It has shown promise in enhancing immune responses, particularly in combating infections like tuberculosis. Research indicates its ability to stimulate T-cell activity, which plays a crucial role in the body's defense mechanism against pathogens. Additionally, it is being explored for its potential use in cancer therapy, as it may help in boosting the immune system to fight tumor cells. Its application in wound healing and tissue repair is also under study, leveraging its role in modulating immune responses to promote recovery. In clinical trials, Golotimod has demonstrated potential in reducing the severity of certain conditions by improving immune function, making it a noteworthy compound in the development of immunotherapeutic treatments.